These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21929482)

  • 21. Translating clinical trial data into new patterns of practice.
    Peragallo-Dittko V
    Diabetes Educ; 2009; 35 Suppl 1():18S-21S. PubMed ID: 19218563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
    Nauck MA; Meier JJ; Schmidt WE
    Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
    [No Abstract]   [Full Text] [Related]  

  • 23. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretin-based therapies for type 2 diabetes: a nurse's perspective.
    Hodgkiss J
    Br J Nurs; 2010 Nov 25-Dec 8; 19(21):1337-8, 1340-4. PubMed ID: 21355358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs for type 2 diabetes.
    Treat Guidel Med Lett; 2011 Aug; 9(108):47-54. PubMed ID: 21778966
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M; Rayfield EJ
    Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
    Moses A
    BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
    [No Abstract]   [Full Text] [Related]  

  • 29. Incretins and risk of neoplasia.
    Halfdanarson TR; Pannala R
    BMJ; 2013 Jun; 346():f3750. PubMed ID: 23751908
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of incretin-based therapies in prediabetes: a review.
    Ahmadieh H; Azar ST
    Prim Care Diabetes; 2014 Dec; 8(4):286-94. PubMed ID: 24666932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incretin Physiology and Pharmacology in the Intensive Care Unit.
    Plummer MP; Hermanides J; Deane AM
    Crit Care Clin; 2019 Apr; 35(2):341-355. PubMed ID: 30784614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
    Chai S; Yu S; Yang Z; Wu S; Gao L; Wang H; Zhang Y; Zhan S; Ji L; Sun F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000728. PubMed ID: 31641525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
    Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
    Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Incretin-Based Therapies on Adipokines and Adiponectin.
    Yaribeygi H; Maleki M; Atkin SL; Jamialahmadi T; Sahebkar A
    J Diabetes Res; 2021; 2021():3331865. PubMed ID: 34660808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

  • 38. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
    Dedov II; Shestakova MV; Sukhareva OIu
    Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Incretin mimetic drugs: therapeutic positioning].
    López Simarro F
    Semergen; 2014 Jul; 40 Suppl 2():25-33. PubMed ID: 25311717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.